Condition: Primary Immune Regulatory Disorder · Autoimmune Lymphoproliferative · Immune System Diseases · Sponsor: Joseph Oved
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells. "Funding Source - FDA OOPD"
This description comes directly from the study's public registry record.
Joseph Oved, MD · 212 305 9770 · jho2001@cumc.columbia.edu
Always discuss trial participation with your own doctor first.
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge, New Jersey, United States | Active Not Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown, New Jersey, United States | Active Not Recruiting |
| Memorial Sloan Kettering Bergen | Montvale, New Jersey, United States | Active Not Recruiting |
| Memorial Sloan Kettering Suffolk - Commack | Commack, New York, United States | Active Not Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Active Not Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Active Not Recruiting |
| Memorial Sloan Kettering Nassau | Rockville Centre, New York, United States | Active Not Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05787574